Phase 3 N=173 Premedication Trial for Tracheal Intubation of the NEOnate
Premedication · Endotracheal Intubation
Primary: Number of Patients With Prolonged Desaturation — 54; 53 Participants — p=0.38
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=3,836 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
Asthma
Primary: 'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No) — 34.4; 31.1; 44.4 Percentage — p=0.046
Phase 3 N=802 Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma
Mild Asthma
Primary: Trough FEV1 — 2.562; 2.379 Liters — p=<0.001
Phase 3 N=841 A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Neoplasms
Primary: Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components) — 8.79; 5.95; 1.90; 2.14 Percentage of participants…
Phase 3 N=97 A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)
Cystic Fibrosis
Primary: Incidence of Respiratory Adverse Events of Special Interest (RAESIs) — 10; 7 Participants
Phase 3 N=69 A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain
Pain
Primary: Number of Participants Classified as Responder (Part 1) — 19; 32 Participants — p=0.0790
Phase 3 N=71 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Refractory Peripheral T-Cell Lymphoma · Relapsed T-Cell Lymphoma
Primary: Objective Response Rate(ORR) by International Working Group Criteria — 37 Participants
Phase 3 N=2,250 Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants
Pneumonia, Pneumococcal
Primary: Serotype-specific Geometric Mean Concentration of IgG Antibody — 4.08; 4.24; 4.58; 1.34 µg/mL
Phase 3 N=95 Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
Hypogonadism, Male
Primary: Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range — 80 Percent of participants
Phase 3 N=330 A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Number of Participants to Experience a Treatment Emergent Adverse Event (TEAE) — 90; 89; 48; 10 Participants
Phase 3 N=100 Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)
Hypogonadism, Male
Primary: Percent of LPCN 1021-treated Subjects Who Achieve a Total Testosterone Average Concentration [Cavg] in the Normal Range — 69 Percent of participants
Phase 3 N=207 A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
Behçet's Syndrome
Primary: Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12) — 222.14; 129.54 Ulcers*days — p=<0.0001
Phase 3 N=61 Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Treatment Responder — 9; 4 Participants
Phase 3 N=180 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
Dry Eye
Primary: Change From Baseline in Tear Break up Time(TBUT ) at Day 84 — 1.45; 1.23 seconds
Phase 3 N=160 Music vs Midazolam During Preop Nerve Block Placement
Anxiety · Peripheral Nerve Block
Primary: Anxiety Levels — 33.3; 30; 30; 23.3 score on a scale